Better Health for All

Bio-Techne's core business provides reagents, instruments, and services for research and clinical diagnostics, supporting areas such as cancer, immunology, neuroscience, regenerative medicine, and Alzheimer's research. This includes advancing Alzheimer's research through the Ella™ automated immunoassay platform and pTau217 detection, enhancing diagnostic efficiency

, and supporting cell and gene therapy development through investment in a GMP facility for cytokines and growth factors . The Diagnostics segment's 16% revenue increase to $87.5 million reflects demand for tools contributing to improved public health outcomes . The company's products do not have addiction potential, and it does not produce food or nutritional products. It is not a pharmaceutical company holding patents on treatments, nor does it conduct clinical trials.

Fair Money & Economic Opportunity

Bio-Techne Corporation operates in the biotechnology sector, focusing on life sciences tools and services.

The company's activities do not directly relate to financial services, fair financial practices, or economic opportunity initiatives such as lending, insurance, or deposit services. There is no evidence of direct engagement in financial empowerment, inclusion efforts, or the provision of financial products to consumers.

Fair Pay & Worker Respect

Bio-Techne settled a lawsuit in October 2024 regarding a religious exemption for COVID-19 vaccine mandates.

The company reported 87% positive feedback from employee surveys, indicating a healthy workplace culture.

Fair Trade & Ethical Sourcing

Bio-Techne has a Supplier Code of Conduct that outlines expectations for suppliers, including the prohibition of child labor.

The company conducts due diligence for conflict minerals, consistent with OECD guidelines, and publishes a Conflict Minerals Report , requiring suppliers to ensure products are DRC Conflict Free under the Dodd-Frank Act. Bio-Techne completed its first EcoVadis sustainability assessment in 2024 , earning a Bronze Medal and ranking in the top 67% of all companies assessed , which included an evaluation of sustainable procurement. The company acknowledges challenges in determining the origin of certain minerals due to supply chain complexity.

Honest & Fair Business

The company has 88.89% independent directors on its board (8 out of 9), with all board committees being 100% independent.

It has maintained a clean financial record, with unchecked boxes in its financial filing (fiscal year end June 30, 2024) explicitly indicating no error corrections or restatements. The company demonstrates strong ethical performance, earning an EcoVadis Bronze Medal with a score of 63, placing it in the top 25% of companies assessed for sustainability, including ethics. Furthermore, Bio-Techne operates a financial fraud and ethics reporting hotline, which is confidential, third-party operated, and supervised by the Chief Compliance Officer with full investigation powers from the Audit Committee, ensuring prompt handling of complaints related to accounting and auditing matters.

Kind to Animals

Bio-Techne Corporation conducts animal testing for some medical products and clinical research.

While the company actively promotes the transition to serum-free and animal-free research methodologies to reduce animal use , its public policy commits to reduction in principle but lacks measurable goals and accountability for its animal testing practices. There is no evidence that any of its animal-related operations hold recognized humane certifications. The company employs several non-animal testing methods, such as cell-based assays and analytical techniques , for internal safety and efficacy assessments, though animal tests still dominate for certain medical products and clinical research. Bio-Techne has made significant strides in substituting animal-derived inputs, establishing dedicated animal-free manufacturing facilities for recombinant proteins and cell culture media. These facilities utilize E. coli expression systems and ensure all raw materials are traceable and certified as animal-free , achieving approximately 50% substitution of animal inputs with high-performance alternatives in these core product lines. The company does not source eggs, meat, or dairy, nor does it have animal agriculture operations.

No War, No Weapons

Bio-Techne maintains an arms-free position, with no links to weapons manufacturing, and its contracts with military branches are for diagnostic healthcare services.

This indicates 0% revenue from arms or defense contracts and no defense business for the board to oversee or assets to divest. The company's ethical red lines codify bans on all categories of conventional arms, with 100% compliance in core business operations. Furthermore, Bio-Techne ensures its products are DRC Conflict Free, complying with the Conflict Minerals provision of the Dodd-Frank Act, indicating 100% of relevant materials are certified conflict-free.

Planet-Friendly Business

Bio-Techne has committed to setting Scope 1, 2, and 3 greenhouse gas reduction targets

and plans to submit them to the Science Based Targets initiative (SBTi) for validation in 2026.

Respect for Cultures & Communities

No specific, quantifiable evidence directly attributable to Bio-Techne Corp or its explicitly stated brands (R&D Systems, Novus Biologicals, Tocris Bioscience, ProteinSimple) was found in the provided articles for any of the KPIs under 'Respect for Cultures & Communities'. While some articles contained relevant data points, they pertained to other companies (Corning, Variant Bio) not identified as part of Bio-Techne Corp's operations or brands. The Native American Council at Corning has partnered with their Talent Acquisition group.

Corning has 17 Employee Resource Groups in Corning, NY, and 34 groups globally. Rita Shauger joined Corning in March 2000. The Native American Council at Corning has partnered with their Talent Acquisition group for 18+ years. The Native American population is less than 1% of the US population. Lora Marden has 15 years of experience working in the rare disease biotech space and social services. Rita Shauger received the EDGE Excellence Award for Diversity in 2017 and Springboard’s Disability Matters Disability Champion Award in 2015. Lora Marden has 14 years of career experience. Variant Bio has worked with Indigenous communities across nine countries or territories. Variant Bio announced a multimillion-dollar deal with a pharmaceutical company, and some of that money will go to the Indigenous communities with whom the firm worked. Variant Bio worked with communities in nine countries or territories. 4% of Variant Bio's revenue and, if the company is ever sold or goes public, 4% of its equity will be shared with communities. Up to 10 percent of a project’s budget goes toward community programs. $100,000 spent to fund several local health organizations along with scholarships and scientific conferences for Indigenous people as part of its New Zealand-based study. A collaboration between Variant Bio and Novo Nordisk is worth $50 million. Variant Bio received $16 million in seed funding from Lux Capital. Information about Bio-Techne's general charitable activities, internal diversity metrics, or business distribution partnerships did not meet the specific criteria for the defined KPIs. Approximately 3,100 full-time and part-time employees as of June 30, 2025 (approximately 2,300 in the United States and approximately 800 outside the United States). Approximately 44% of our sales revenue in fiscal 2025 coming from outside the U.S. As of June 30, 2025, 48% of our total employee population was female, and 43% of our managerial employees were female. 39% of our total employee population identified as nonwhite and 28% of our managerial employees identified as nonwhite. As of June 30, 2025, we had 11 ERGs operating globally. Strategic distribution partnerships with Medsantek and Leader Life Sciences to expand footprint in Turkey and the Middle East. Over $1.2 billion in fiscal year 2025. Technologies cited more than 32,000 times in peer-reviewed publications in calendar year 2024. In 2025, two-thirds of our global workforce participated in an engagement survey, and 75% of those who responded provided favorable feedback. United States employees receive a paid day off to participate in local opportunities to give back to the community as part of our volunteer time off benefit. Most sites or departments engage in local charitable causes and activities. In 2024, Bio-Techne completed a priority assessment to identify impacts, risks, and opportunities related to sustainability. Bio-Techne plans to submit Scope 1, 2, and 3 greenhouse gas (GHG) emissions reduction targets to the Science Based Targets initiative (SBTi) for validation in 2026. 8% of revenue is invested in Research and Development.

Safe & Smart Tech

Bio-Techne has reported no material cybersecurity threats

and expects no material financial impact from such threats. The company maintains a comprehensive cybersecurity governance framework, with oversight from its Board and an Incident Response Team led by a CISO. They implement measures including patching, employee training, and network monitoring. Bio-Techne also complies with various data privacy regulations such as HIPAA, CCPA, and GDPR, supported by robust internal controls and regular compliance reviews.

Zero Waste & Sustainable Products

Bio-Techne has implemented a Design for Sustainability framework, classifying product attributes that contribute to sustainability.

This includes an increased emphasis on efficiency and resource-conscious design in the development of cell therapy workflows, proteomic analytical instruments, spatial biology, and precision diagnostics , as well as for Simple Western assays which aim to minimize waste by reducing plastic and water usage. The company also hosts low waste events and has increased compost and recycling options as part of its waste reduction initiatives.